Results 71 to 80 of about 4,565 (192)
Clinical Pharmacology: Advances and Applications, 2022 Erika Rijavec,1 Federica Biello,2 Alice Indini,3 Francesco Grossi,3 Carlo Genova4,5 1Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 2Division of Oncology, Department of Translational Medicine, University ...
Rijavec E +4 more
doaj
Decoding Gene Expression Changes in Cerebral Tumors: Before and After Radiotherapy
Medicinal Research Reviews, Volume 45, Issue 6, Page 1651-1661, November 2025.ABSTRACT Cerebral tumors, particularly in pediatric patients, pose a significant challenge in oncology. Radiotherapy is a crucial component of the multimodal treatment approach for these tumors. Understanding the molecular basis of these tumors, particularly their response to radiotherapy, is crucial for improving treatment outcomes and patient ...
Ahana Maitra +9 more
wiley +1 more source
Lung Cancer: Targets and Therapy, 2023 Alexandria TM Lee,1 Saihong Ignatius Ou1,2 1University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Saihong Ignatius Ou, University of ...
Lee AT, Ou SI
doaj
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. [PDF]
, 2019 PurposeDiarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.MethodsThis paper reviews data on the ...
Bosserman, Linda +6 more
core
Thoracic Cancer, Volume 16, Issue 21, November 2025.Inhibition of EML‐ALK function by TKI. In cells, not treated with TKI, ATP binding occurs in the active site (pocket) of the hybrid protein, leading to its activation and functional effects. Introduction of a TKI leads to TKI compete with ATP for binding to the active site.
Elena Klenova
wiley +1 more source
Saudi Pharmaceutical Journal, 2018 The mortality rate in patients suffering from non-small cell lung cancer (NSCLC) is quite high. This type of cancer mainly occurs due to rearrangements in the anaplastic lymphoma kinase (ALK) gene which leads to form an oncogene of fused gene NPM-ALK ...
Silky Bedi +5 more
doaj +1 more source
Chemistry – A European Journal, Volume 31, Issue 59, October 22, 2025.The development of broadly useful C‐P cross‐couplings of (hetero)aryl chlorides and HP(O)(R/OR)2 nucleophiles by use of nickel/DalPhos‐based catalysts is described, along with findings from DFT studies that confirm the preference for C‐P bond formation in this system arising from three‐cantered reductive elimination through substrate PV pathways ...
Michael J. Cotnam +5 more
wiley +1 more source
ALK inhibitors in ALK-positive NSCLC with central nervous system metastases [PDF]
, 2020 In anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer, brain metastases occur in 22–33% of cases at diagnosis and could reach up to 70% after crizotinib failure.
Aldea, Mihaela +2 more
core +2 more sources
Cancer MedicinePurpose There is a lack of real‐world data in Asian populations for brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non‐small cell lung cancer (NSCLC). This study analysed real‐world outcomes and dosing patterns
Jeong Eun Lee +4 more
doaj +1 more source
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer [PDF]
, 2019 Lung cancer still represents the leading cause of cancer-related mortality. However, the recent advent of tyrosine kinase inhibitors (TKI), pioneering drugs against targetable mutations, have dramatically improved prognosis of advanced non-small cell ...
Mariniello, Annapaola +2 more
core +1 more source